Cdk inhibitors in development and cancer

被引：2
|
作者：
Harper, JW
Elledge, SJ
机构：
[1] BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030
[2] BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030
来源：
CURRENT OPINION IN GENETICS & DEVELOPMENT | 1996年 / 6卷 / 01期
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Activation of cyclin-dependent kinases is the primary control point of cell proliferation. Recent advances in the understanding of cell-cycle regulation have uncovered two families of proteins that bind and inhibit these kinases. These proteins are likely mediators of development and differentiation, and may provide molecular connections between the pathways of development and tumorigenesis.
引用
下载
收藏
页码：56 / 64
页数：9
相关论文
共 50 条
  • [31] Treating cancer with selective CDK4/6 inhibitors
    Ben O'Leary
    Richard S. Finn
    Nicholas C. Turner
    Nature Reviews Clinical Oncology, 2016, 13 : 417 - 430
  • [32] Update on CDK4/6 Inhibitors in Breast Cancer
    Tolaney, Sara M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (06) : 298 - 300
  • [33] The Role of CDK4/6 Inhibitors in Breast Cancer
    Murphy, Conleth G.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (06)
  • [34] CDK inhibitors in hormone receptor positive advanced breast cancer
    Aktas, Bilge
    MARMARA MEDICAL JOURNAL, 2015, 28 (04): : 35 - 39
  • [35] The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment
    Witzel, Isabell
    Mueller, Volkmar
    BREAST CARE, 2016, 11 (03) : 165 - 166
  • [36] Molecular Pathways: CDK4 Inhibitors for Cancer Therapy
    Dickson, Mark A.
    CLINICAL CANCER RESEARCH, 2014, 20 (13) : 3379 - 3383
  • [37] Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy
    Rana, Sandeep
    Sonawane, Yogesh A.
    Taylor, Margaret A.
    Kizhake, Smitha
    Zahid, Muhammad
    Natarajan, Amarnath
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (23-24) : 3736 - 3740
  • [38] Biomarker Discovery for Cancer Sensitivity to CDK8 Inhibitors
    Lu, Zhixin
    Spear, Jensen E.
    Russu, Wade A.
    FASEB JOURNAL, 2018, 32 (01):
  • [39] Treating cancer with selective CDK4/6 inhibitors
    O'Leary, Ben
    Finn, Richard S.
    Turner, Nicholas C.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (07) : 417 - 430
  • [40] The Role of CDK4/6 Inhibitors in Breast Cancer
    Conleth G. Murphy
    Current Treatment Options in Oncology, 2019, 20
12345